VF
TCRR

Virtu Financial’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Virtu Financial’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-19,204
Closed -$19K – 2389
2022
Q4 		$19K Buy
+19,204
New +$25.9K ﹤0.01% 1284
2022
Q1 		– Sell
-31,912
Closed -$149K – 2313
2021
Q4 		$149K Buy
+31,912
New +$200K 0.02% 961
2021
Q2 		– Sell
-16,384
Closed -$362K – 2249
2021
Q1 		$362K Buy
+16,384
New +$447K 0.03% 699

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Virtu Financial's TCRR Position: Q1 2023 in Review

Virtu Financial sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q1 2023, closing a stake of 19,204 shares — an estimated $19K sold.

Virtu Financial first reported a position in TCRR in Q1 2021 and held it in 3 quarters. The position peaked at $362K in Q1 2021. 59 funds tracked by Wall St. Rank hold TCRR as of Q1 2023.

  • Virtu Financial reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Virtu Financial sold 19,204 TCR2 Therapeutics Inc. Common Stock shares in Q1 2023, an estimated $19K.
  • Virtu Financial first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2021 and held it in 3 quarters.
  • Virtu Financial's TCR2 Therapeutics Inc. Common Stock position peaked at $362K in Q1 2021.
  • 59 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q1 2023.

Based on Virtu Financial's 13F filing for Q1 2023, filed 1 May 2023.